61 results
CORRESP
TXMD
TherapeuticsMD Inc
19 Jul 07
Correspondence with SEC
12:00am
to the sale of marketable securities and hedging transactions during fiscal year December 2002. The capital loss has indefinite life and can only used … 31, 2006, the Company had capital loss carry-forwards of approximately $31,000. The loss was due to the sale of marketable securities and hedging
424B3
TXMD
TherapeuticsMD Inc
24 Dec 13
Prospectus supplement
12:00am
or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise;
broker-dealers may agree … customary in the type of transactions involved). In connection with sales of the Shares or otherwise, the Selling Stockholders may enter into hedging
CORRESP
TXMD
TherapeuticsMD Inc
30 Jul 07
Correspondence with SEC
12:00am
$31,000. The loss was due to the sale of marketable securities and hedging transactions during fiscal year December, 2002. The capital loss has indefinite
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
30 Jul 09
Index to Financial Statements
12:00am
Instruments and Hedging Activities, an amendment of FASB Statement No. 133 (“SFAS 161”). SFAS 161 requires enhanced disclosures about an entity’s … derivative and hedging activities. These enhanced disclosures will discuss: how and why an entity uses derivative instruments; how derivative instruments
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
14 Jun 10
Index to Financial Statements
12:00am
ASC 815,Disclosures about Derivative Instruments and Hedging Activities”, (“ASC 815”). ASC 815 requires enhanced disclosures about an entity’s … derivative and hedging activities. These enhanced disclosures will discuss: how and why an entity uses derivative instruments; how derivative instruments
8-K
EX-99.2
b480zkb l5
14 Jun 10
Index to Financial Statements
12:00am
8-K/A
EX-99.1
0tdfeck09 ds
15 Jun 10
Index to Financial Statements
12:00am